Please try another search
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Andrew I. Koven | 65 | 2021 | Independent Chairman of the Board |
D. Gordon Strickland | 76 | 2022 | Independent Director |
Roy Lester Freeman | 70 | - | Chairman of Scientific Advisory Board |
Michael H. Salsbury | 73 | 2019 | Independent Director |
Jason L. Groves | 52 | 2019 | Independent Director |
Caroline M. Apovian | - | - | Member of Scientific Advisory Board |
Mark A. Glickman | 57 | 2023 | Independent Director |
Stephen A. Harrison | - | - | Member of Scientific Advisory Board |
Hyung-Heon Kim | 48 | 2021 | CEO, President, Principal Executive & Director |
James Patrick Tursi | 59 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review